Market Place
Sourcing Support
Aptevo and Alligator Present Positive ALG.APV-527 Data at SITC 2024
29 Oct 2024 //
ACCESSWIRE
Aptevo And Alligator Announce ALG.APV-527 Trial Data
16 Sep 2024 //
ACCESSWIRE
Aptevo And Alligator Present ALG.APV-527 Data For Solid Tumors At ESMO
13 Sep 2024 //
ACCESSWIRE
ASCO 2024: Alligator shares positive data for pancreatic cancer drug
04 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
07 Mar 2024 //
ACCESSWIRE
First-line Mitazalimab Plus Chemo Continues to Generate Responses in PDAC
27 Jun 2023 //
ONCOLIVE
Alligator & Aptevo Announce Dosing of First Patient with ALG.APV-527 in PI Trial
13 Feb 2023 //
ACCESSWIRE
Orion & Alligator reveal second stage of immuno-oncology research collaboration
03 Jan 2023 //
PHARMA TIMES
Alligator Announces +ve Interim Results from Mitazalimab OPTIMIZE-1 Ph 2 Trial
02 Jan 2023 //
PIPELINEREVIEW
Alligator Bioscience & Aptevo Announce Publication Highlighting ALG.APV-527 s
09 Nov 2022 //
ACCESSWIRE
Alligator Announces IND Approval for Second Phase 2 Clinical Trial of AC101
08 Nov 2022 //
PRESS RELEASE
Alligator Bioscience announces positive safety data from ATOR-1017 study
30 Sep 2022 //
PHARMATIMES
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued
19 Sep 2022 //
ACCESSWIRE
Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1
14 Sep 2022 //
MFN
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update
23 Mar 2022 //
PRNEWSWIRE
Alligator Bio initiates sponsored research agreement with UPENN
20 Jan 2022 //
PHARMABIZ
Alligator reports update on-going OPTIMIZE-1 phase Ib/II trial with mitazalimab
19 Jan 2022 //
PHARMABIZ
Alligator Announces Trial Update and Early Readout for ATOR-1017
15 Dec 2021 //
PRNEWSWIRE
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
08 Nov 2021 //
PRNEWSWIRE
Alligator is exploring financing alternatives to support phase II studies
02 Sep 2021 //
PRNEWSWIRE
Alligator announces Collaboration and License Agreement with Orion Corporation
18 Aug 2021 //
PRNEWSWIRE
Article on CD40 agonistic antibodies published in Expert Opinion
07 Jun 2021 //
BIOSPACE
Alligator`s mitazalimab shown to enhance cancer vaccine
06 May 2021 //
PRNEWSWIRE
Alligator & MacroGenics Enter into a Research Collaboration to Develop
16 Apr 2021 //
PRNEWSWIRE
Alligator and MacroGenics Enter into a Research Collaboration
15 Apr 2021 //
BIOSPACE
Alligator Bioscience appoints Søren Bregenholt as new CEO
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience appoints Søren Bregenholt as new CEO
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience publishes Annual Report for 2020
18 Mar 2021 //
PRNEWSWIRE
Alligator Bioscience AB: Year-end Report January-December 2020
26 Feb 2021 //
PRNEWSWIRE
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
28 Dec 2020 //
PRNEWSWIRE
Alligator Bioscience recruits new Chief Medical Officer
28 Dec 2020 //
PRNEWSWIRE
Alligator seeks regulatory approval to begin ph II OPTIMIZE-1 of mitazalimab
28 Dec 2020 //
PHARMABIZ
Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
28 Dec 2020 //
PRNEWSWIRE
Alligator Bioscience recruits new Chief Medical Officer
28 Dec 2020 //
PRNEWSWIRE
Alligator seeks regulatory approval to begin ph II OPTIMIZE-1 of mitazalimab
28 Dec 2020 //
PHARMABIZ
Alligator Bioscience`s IND for CD40 antibody mitazalimab gets US FDA approval
06 Dec 2020 //
PHARMABIZ
Alligator Bioscience presents at the SITC 35th Annual Meeting
09 Nov 2020 //
PRNEWSWIRE
Alligator presents the CD40 antibody mitazalimab at the World Immunotherapy
04 Nov 2020 //
BIOSPACE
Alligator presents the CD40 antibody mitazalimab at the World Immunotherapy
04 Nov 2020 //
PRNEWSWIRE
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
22 Oct 2020 //
PRNEWSWIRE
Alligator Bioscience AB (publ): Interim report January-September 2020
21 Oct 2020 //
PRNEWSWIRE
Alligator presents positive biomarker data proof of mechanism mitazalimab
04 Sep 2020 //
PRNEWSWIRE
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 Ph I study
26 Aug 2020 //
PRNEWSWIRE
Alligator Bioscience: Encouraging interim safety data in ATOR-1017
26 Aug 2020 //
PRNEWSWIRE
Alligator Bioscience presents the clinical project portfolio at Virtual R&D
25 Aug 2020 //
PRNEWSWIRE
Alligator Bioscience receives first patent approval for ATOR-1017
23 Jun 2020 //
CISION
Alligator Bioscience Appoints New CFO
15 Jun 2020 //
PRNEWSWIRE
Aptevo and Alligator Bioscience Present new Preclinical Data for ALG.APV-527
10 Jun 2020 //
PRNEWSWIRE
Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement
04 Jun 2020 //
PRNEWSWIRE
Alligator Bioscience`s Collaboration With Biotheus Proceeds and Second Payment
01 Jun 2020 //
PRNEWSWIRE
Alligator Presents Novel Supportive PhI Data at ASCO for its CTLA-4 x OX40
29 May 2020 //
PRNEWSWIRE
Alligator Bioscience Presents Promising Interim Ph I Data for its ATOR-1015
27 Apr 2020 //
PR NEWSWIRE
Alligator Bioscience Presents Interim Ph I Data its Bispecific Drug ATOR-1015
27 Apr 2020 //
PR NEWSWIRE
Alligator Bioscience Increases Focus on Clinical Development
07 Apr 2020 //
PR NEWSWIRE
Alligator Bioscience Increases Focus on Clinical Development
06 Apr 2020 //
PR NEWSWIRE
Alligator Bioscience: First Patient Dosed With ATOR-1017
17 Dec 2019 //
BIO SPACE
Alligator Bioscience AB Appoints Chief Operating Officer
30 Nov 2019 //
PR NEWSWIRE
Alligator Bioscience signs antibody agreement for Greater China
21 Aug 2019 //
BIOSPECTRUMASIA
Janssen returns rights for experimental cancer immunotherapy to Alligator
02 Aug 2019 //
PHARMAFILE
Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO
16 May 2019 //
PR NEWSWIRE
